The authors present a stereotypical case presentation of X-linked hypophosphatemia (XLH) and provide a review of the pathophysiology and related pharmacology of this condition, primarily focusing on the FDA-approved medication...
300 targets using very small quantities of protein. This revealed decreased activation of the mTOR pathway in tibiae of Nmu knock-out mice compared to controls, with reduced activity-associated phosphorylation of mTOR and the...
Current therapies for low bone mass consist of inhibiting osteoclast activity or increasing the PTH or Wnt signaling pathways. These approaches have significant drawbacks that limit their use in specific patient populations...